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Summary
What is already known?
 Ź There are 48 known NHS e-therapies that are used/
recommended.
 Ź The landscape for assessing apps is complex and 
ever-changing.
What does this paper add?
 Ź A comprehensive analysis of the development pro-
cesses behind the e-therapies used and recom-
mended for common mental health problems across 
the National Health Service (NHS) in England.
 Ź A list of areas that most need reinement to improve 
e-therapy suitability for NHS mental health services.
ABSTRACT
Objective To document the quality of web and 
smartphone apps used and recommended for stress, 
anxiety or depression by examining the manner in which 
they were developed.
Design The study was conducted using a survey sent to 
developers of National Health Service (NHS) e-therapies.
Data sources Data were collected via a survey sent out 
to NHS e-therapy developers during October 2015 and 
review of development company websites during October 
2015.
Data collection/extraction methods Data were compiled 
from responses to the survey and development company 
websites of the NHS e-therapies developers.
Results A total of 36 (76.6%) out of the 48 app 
developers responded. One app was excluded due to its 
contact details and developer website being unidentiiable. 
Data from the missing 10 was determined from the app 
developer’s website. The results were that 12 out of 13 
web apps and 20 out of 34 smartphone apps had clinical 
involvement in their development. Nine out of 13 web apps 
and nine out of 34 smartphone apps indicated academic 
involvement in their development. Twelve out of 13 web 
apps and nine out of 34 smartphone apps indicated 
published research evidence relating to their app. Ten 
out of 13 web apps and 10 out of 34 smartphone apps 
indicated having other evidence relating to their app. 
Nine out of 13 web apps and 19 out of 34 smartphone 
apps indicated having a psychological approach or theory 
behind their app.
Conclusions As an increasing number of developers are 
looking to produce e-therapies for the NHS it is essential 
they apply clinical and academic best practices to ensure 
the creation of safe and effective apps.
INTRODUCTION
While apps can have the potential to give 
great benefits, they also have the potential to 
cause physical, mental, reputational or finan-
cial harm to patients, healthcare professionals 
and their organisations if they are not evalu-
ated for clinical safety. For example, an app 
may miscalculate a drug dose or give incor-
rect medical advice to a consumer or patient. 
National Health Service (NHS) digital high-
lights that apps to be used by the NHS cannot 
be endorsed unless they have been evaluated 
for potential harm,1 while Public Health 
England’s (PHE’s) health app assessment 
process requires developers to outline plans 
and policies to limit and mitigate potential 
risks associated with their apps. This paper 
is concerned with web and smartphone apps 
designed to offer treatment or support with 
the common mental health problems of 
depression, anxiety and stress—collectively 
herein termed ‘e-therapies’, which are used 
or recommended by the NHS in England. 
It is important to note that the landscape 
of e-therapies shifts rapidly, and indeed has 
done so since the data presented here were 
collected 4 years ago.
Regulatory approval provides patients 
and healthcare professionals with the assur-
ance that an app is of high quality, safe and 
ethical.1 There are two types of regulation 
presently available in the UK: the Medicines 
and Healthcare products Regulatory Agency 
(MHRA) Medical Device Registration and 
Care Quality Commission (CQC) Registra-
tion. Both are relevant to e-therapies. MHRA 
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provides a ‘device determination’ flowchart that enables 
developers to check whether their app is defined as a 
medical device. The two main questions in determining 
this are whether the app has a medical purpose and 
whether it works directly with data obtained in vivo. At 
the time of writing, developers of apps that meet these 
criteria and who want to market them to the public are 
required by UK regulation to register the app with the 
MHRA and to obtain for it a Conformité Européenne 
(CE) marking, indicating conformity with health, safety 
and environmental protection standards for products 
sold within the European Economic Area.2
CQC set out 14 regulated activities: personal care; 
accommodation for people who require nursing or 
personal care; accommodation for people who require 
treatment for substance misuse; treatment of disease, 
disorder or injury; assessment or medical treatment for 
persons detained under the Mental Health Act 1983; 
surgical procedures; diagnostic and screening proce-
dures; management of supply of blood and blood-derived 
products; transport services; triage and medical advice 
provided remotely; maternity and midwifery services; 
termination of pregnancies; services in slimming clinics; 
nursing care and family planning services. If an app 
provides a health or social care service that fits one of 
these activities the developers are required by the PHE to 
register with the CQC before the app can be accessed via 
the PHE app assessment process.
It is essential for the public to know whether an 
e-therapy is effective. Some have argued that many 
apps have no evidence to support their effectiveness,3 
but deciding what constitutes ‘evidence’ for apps is not 
straightforward. Within healthcare research, there is a 
hierarchical structure depicting the strength of evidence.4 
The higher the level, the greater the internal validity and 
hence the more persuasive and trustworthy the evidence 
is. The randomised controlled trial (RCT) is currently 
the gold standard for providing evidence of clinical effi-
cacy.4 However, RCTs take time to design, implement and 
publish and thus are poorly matched to the pace at which 
technologies and tools are evolving. This means that 
there is presently no clear consensus on how best to eval-
uate apps, although policymaker and researcher efforts 
are being directed to the issue, as outlined below.
An European Union Working Group was set up in 
February 2016 to create mHealth assessment guidelines 
but unfortunately failed to reach a conclusion.5 A report 
by the group highlighted that building the guidelines had 
been found to be a much more complex exercise than 
initially expected at the beginning of the process, and the 
work required went far beyond the original mandate of 
the group.6
Separately to this, a toolkit for appraising e-therapies 
was developed and released by MindTech in October 
2017. The toolkit offers a standard set of criteria for 
evaluating existing digital mental health tools (apps and 
mobile websites) and a final report discussing the frame-
work was published.7 Other examples of app assessment 
methods that have been developed in recent years 
include the Mobile App Rating Scale (MARS), devel-
oped by an Australian research team in 2015.8 MARS is 
a scale that aims to provide researchers, clinicians and 
developers with a way to score digital tools based on a 
list of evaluation criteria.8 Item 19 of the scale regarding 
clinical evidence was ignored due to researchers having 
yet to test the impact of the mental health apps included 
in the study.8 Similarly, the British Standards Institution 
in conjunction with Innovate UK has developed the 
PAS 277:20 159 code of practice. The PAS recommends 
during the preliminary stages of app development that 
developers read academic research to ensure that their 
app is built on clinical evidence. It also recommends that 
app publishers/developers should collect data during 
testing with users to validate any clinical benefits that the 
app’s intended use delivers9; such an exercise would likely 
require the require involvement of academic researchers 
to ensure the evidence was of a sufficiently high standard. 
As well as helping to design new tools, the code can be 
used to evaluate existing ones.9
In October 2017, PHE released a health app assess-
ment process developed to encourage the creation of 
effective health apps and to enable health professionals 
to consider health apps for use in General Practice.10 
The process covered eight different areas: evidence of 
effectiveness; regulatory approval; clinical safety; privacy 
and confidentiality; security; usability and accessibility; 
interoperability; and finally, technical stability.
More recently, NHS digital have introduced a Beta 
Digital Assessment Questionnaire (DAQ) 1.2 for the 
assessment of mobile apps11 and the National Institute 
for Health and Care Excellence (NICE), along with their 
partner organisations have published a set of evidence 
standards for digital health technologies which includes 
apps.12 The evidence standards have been developed to 
ensure new technologies are clinically effective and repre-
sent value for money to the NHS, while also aiming to 
make it easier for innovators and commissioners to under-
stand what good levels of effectiveness for digital technol-
ogies should look like. NHS Digital is working closely with 
NICE to incorporate these standards into future versions 
of the DAQ.11
Current study
It is apparent that the landscape for assessing apps is 
complex and ever-changing. The aim of the present study 
was to examine the quality of apps in use by the NHS by 
examining the manner in which they have been devel-
oped. At the time of this study, the majority of existing 
app review methods either focused on the technical rules 
and regulations of app design and overlooked (often by 
necessity, MARS8) the question of effectiveness, that is, 
whether the actual app does what it says and meets the 
claims its developers make for it. While this has been 
rectified in the DAQ,11 the current research precedes this. 
In an ideal world, before being released for general use, 
every app would have undergone rigorous user trials that 
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demonstrated its effectiveness. However, rigorous trials 
are a costly and challenging business, and current models 
of app development and publishing seem to encourage 
less rigorous approaches. Here, in an attempt to gauge 
the quality of existing apps as providers of therapy without 
performing user trials on each and every one, we have 
adopted the approach of probing more deeply into the 
processes employed in their development. More specifi-
cally, we are interested in the psychological model, theo-
ries, or therapies used, the extent of clinical and academic 
involvement, and any published (or otherwise) evidence 
in support of each app. The developers of each of the 
apps identified in our previous study13 were contacted 
and asked to provide the relevant details. It is worth 
noting that the quality assessment frameworks detailed 
above did not precede the development of many of the 
apps reviewed here, so developers were likely operating in 
a quality assessment vacuum at the time of creating their 
products.
Important indicators of quality
The purpose of this study was to evaluate the apps that 
were previous identified as being used or recommended 
by the NHS.13 We were specifically interested in the 
following four indicators of quality: clinician involve-
ment, academic involvement, research or other evidence 
and use of a specific psychological approach or theory. 
These indicators were selected because they build on the 
premises that effective digital psychotherapy interven-
tions come about as a result of rigorous theoretical and 
empirical works by experienced clinicians and academics, 
utilising a known psychological approach. We discuss the 
advantages of each below.
Clinician involvement
Healthcare staff routinely use apps to perform their 
roles.14 This makes it essential that the information given 
in these apps be grounded in the best and most up-to-date 
knowledge, derived from research, clinical experience 
and patient preference.1 Unfortunately, many app stores 
do not carry out rigorous reviews regarding the accuracy 
of app content before publication, meaning some apps 
potentially have inaccurate information.15 Other publica-
tions have highlighted that when assessing digital mental 
health apps, it is important to assess whether clinicians 
have been involved in the development process.16 17 This 
is because clinician involvement can help to ensure that 
any established modes of treatment are appropriately 
deployed within the app. For instance, an app based on 
cognitive behaviour therapy (CBT) but made by someone 
who is not qualified to deliver CBT may fail to give an 
accurate implementation. The involvement of a clinician 
who specialises in CBT would improve the quality of app 
content by ensuring treatment fidelity.
Academic involvement
Academic involvement in the process of developing an 
app can help to ensure the implementation of empirically 
supported interventions and principles, providing a foun-
dation for an app’s use in clinical practice. Responsible 
academics strive to bring neutrality and remove bias, to 
expose the app to peer review and publish evidence of 
an app’s feasibility, acceptability and clinical effectiveness.
As mentioned previously it is essential that an app can 
show evidence of its effectiveness. In PHE’s app assessment 
process, developers must provide evidence that their app 
improves outcomes for patients and users; provides value 
for money; meets user needs and is stable and simple 
to use, and that people use it. Independent research is 
weighted highly in the assessment criteria, and apps that 
have a high level of clinical evidence are considered by 
NICE for ‘NICE evaluated’ status. This status is consid-
ered to represent the gold standard for NHS health apps. 
In addition to this, all apps are required to show that 
they meet the criterion set out by NHS Digital covering: 
clarity of purpose and intended use; their evidence basis; 
the data that forms the basis their evidence and findings; 
any published academic studies.1 The involvement of 
academics in the development of an app can be helpful in 
ensuring that data are collected in a manner that makes 
it possible to evaluate effectiveness, although it is also 
important that evaluation is conducted by researchers 
independent of the app, without a personal interest in 
the results.
Research evidence/other evidence
While RCTs are the gold standard, it is not expected that 
all apps will have published research evidence at the 
time of writing in part due to the rapid pace of change 
and the unwieldy nature of conducting RCTs. However, 
there might be other forms of evidence that can indi-
cate whether an app may be beneficial to a patient. This 
evidence may take different forms such as practice-based 
evidence methodologies (eg, detailed case series) that 
assess the acceptability, feasibility and initial effectiveness 
of an app and may also include early pilot trials.
Speciic psychological approach or theory/set of techniques/
therapy
Apps claiming to help with mental health problems 
such as depression, anxiety or stress would be expected 
to use established approaches to treatment that have 
been found to be effective through high quality research 
studies. The psychological therapies that are designated 
by NICE regardless of disorder are all underpinned by 
a clinical theory. The risk of not having an organising 
theoretical framework for an app is that the change tech-
niques that are used may be cherry-picked by developers 
on the basis of inappropriate criteria (eg, selecting tech-
niques that can be gamified easily rather than those that 
are most effective) and so lack theoretical coherence and 
consistency.
Using indicators of quality to evaluate apps
If we accept the premise that effective psychotherapeutic 
interventions only come about as the result of rigorous 
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Table 1 All NHS e-therapy app survey responses by app
App
Web or 
phone 
based 
(w/p)
Clinical 
involvement
Academic 
involvement
Publications 
published or 
forthcoming
Other 
evidence
Psychological 
approach or 
theory
Aventurine Mood 
Improver
P N N Y* Y† Y
Beating the Blues W Y Y Y Y Y
Big White Wall W Y N Y‡ Y‡ Y
Black Rainbow P N N N N N
Buddy App W Y N Y Y§ N¶
Depression 
Calculator**
P Y N N N N
DigitalMeds P N N Y* N Y
Don’t Panic!** P Y N N N Y
Fear Fighter W Y Y Y Y Y
Five Ways to 
Wellbeing
P Y N N Y†† Y
Ginsberg App P Y Y N N Y
Happy Healthy App P Y Y Y Y N
Headspace P N N Y Y Y
Healthstored P N N N N N
Healthy Living** P Y N N N N
Hello Brain Health P Y Y Y‡‡ Y Y
How Are You App P N Y N N Y
iCBT** P Y N N N Y
IESO Digital Health W Y Y Y Y Y
Kooth W Y Y Y* Y N¶¶
Living Life to the Full W Y N Y N Y
Mind Ed W Y Y Y*** N N
Mindfulness Bell** P N N N N N
Mindfulness by 
Digipill**
P Y N N N Y
Mindlogr P N N N N Y
Mindshift P Y N N Y Y
Moodbug P N N N N Y
MoodGym W Y Y Y Y Y
Moodkit—Mood 
Improvement Tools
P Y Y Y Y††† Y
Moodometer P Y N N N Y
Moodscope W Y‡‡‡ Y Y Y Y
MyMoodTracker P N N N N N
Panic Attack Aid** P N N N N N
Phobia Free P Y Y Y§§§ Y¶¶¶ Y
Puffellf W N N N N N
SAM: Self-help for 
Anxiety
P Y Y Y N N
SilverCloud Health W Y Y Y Y Y
Stay Alive P Y N N N N
Continued
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App
Web or 
phone 
based 
(w/p)
Clinical 
involvement
Academic 
involvement
Publications 
published or 
forthcoming
Other 
evidence
Psychological 
approach or 
theory
Stress & Anxiety 
Companion
P Y N N N Y
Stress Management 
App
P Y Y N Y**** Y
Take a break! P Y N N N N
Thought Diary** P N N N N N
Thought Diary Pro** P N N N N N
Virtual Hope Box P Y Y Y Y Y
WellMind P Y N N N N
WorkGuru W Y Y Y†††† Y‡‡‡‡ Y
Worry Watch** P N N N N N
*References studies related to the therapy on which the app was based, rather than the app itself.
†The developer assessed CBT apps in a non-scientiic way.
‡Studies were not published at the time of the survey but were in preparation.
§Piloted within 12 NHS Trusts across a range of services and teams.
¶Designed to work with a behavioural activation framework.
**Failed to respond to survey. Answered by the researcher based on publicly available information.
††Had a testing/pilot phase mainly to see if the elements worked and what people thought about the app.
‡‡No publications but at very early stages of two projects that will produce independent research evidence.
§§PhD student rather than experienced research academic.
¶¶Declared no approach, but on inspection of the developer’s website, it was found that the service offers one-to-one CBT over a messenger.
***Comprehensive systematic review of e-therapies.
†††Currently being evaluated in a large controlled eficacy trial.
‡‡‡Adaption of the PANAS test.
§§§Research carried out independently by Roehampton University and being prepared for submission.
¶¶¶Feasibility study to test acceptability, presented at Royal College Psychiatry 2013 International Congress.
****Piloted to ensure the UX was appealing/useful, and so on but no formal studies.
††††PhD researcher is planning research looking at how to increase engagement with online workplace therapies.
‡‡‡‡2 Non-academic studies without a control group. The developer is currently planning an randomised controlled trial.
CBT, cognitive behaviour therapy; NHS, National Health Service; PANAS, Positive and Negative Affect Schedule; UX, user experience.
Table 1 Continued
Table 2 Summary of key indings by number (N) and 
percentage (%) where yes was the response given
Web Smartphone Overall
Clinical involvement 12 (92%) 20 (59%) 32 (68%)
Academic involvement 9 (69%) 9 (27%) 18 (38%)
Research evidence 12 (92%) 9 (27%) 21 (45%)
Other evidence 10 (77%) 10 (29%) 20 (43%)
Psychological 
approach or theory
9 (69%) 19 (56%) 28 (60%)
theoretical and empirical work by experienced clini-
cians and academics, it follows that apps need clinician 
and academic involvement, psychological theory and 
research/other data to support their effectiveness. We 
have previously collated a list of NHS endorsed e-ther-
apies (meaning therapeutic apps (both phone and 
web) that are used or recommended in NHS settings 
in England)13 designed to target stress, depression, or 
anxiety. In the current study, we evaluate these NHS 
e-therapies for compliance with the indicators of quality 
described above. To do so, we surveyed the developers of 
all the apps identified in our previous study13 regarding 
the key indicators of quality described, and whether there 
were any differences between web and phone apps.
METHODS
Design
We documented development information surrounding 
each of the web and smartphone apps used and recom-
mended by the NHS for stress, anxiety and depression 
identified in our previous study.13 Our data source was 
a survey sent to developers. In the survey, we asked 
for information about clinical involvement, academic 
involvement, publications published or forthcoming, 
other evidence of effectiveness and whether the app was 
based on a psychological approach or theory.
Participants
Participants were the developers of the 48 NHS e-thera-
pies comprised 13 web and 35 smartphone apps. These 
apps were identified in our previous study in which data 
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regarding web and smartphone apps used or recom-
mended were compiled from responses to: (1) freedom 
of information requests sent to all Improving Access to 
Psychological Therapies (IAPT) services and NHS Mental 
Health Trusts in England; and (2) NHS apps library 
search results.13
Procedure
Ethical approval was gained from the University of Shef-
field Psychology Ethics Committee. During October 
2015, each e-therapy developer was initially contacted 
by telephone before being sent an email invitation to be 
involved in a study. Those who expressed interest were 
sent an information sheet and consent form. Those who 
consented were sent a link to the online survey covering 
the five key areas of evidence for the quality of an app, 
namely: the extent of clinical involvement in its develop-
ment; the existence of published evidence; the extent of 
academic involvement; any studies or trials which have 
been undertaken; any psychological approach or theory 
on which the app is based. The questions asked are 
reported in online supplementary table S1. Each initial 
question had a further open-ended subquestion asking 
for more details when a participant confirmed the exis-
tence of that particular evidence. Participants were then 
debriefed.
Statistical analysis
In order to establish whether the answers to these ques-
tions differed as a function of app type (web or phone), 
tests of association were use. A series of χ2 tests were 
conducted for questions 2, 3, 4 and 5. Data from question 
1 did not meet all assumptions for a χ2, so a Fisher’s exact 
test was conducted instead.
RESULTS
Thirty-six (75%) of app developers responded to the 
survey. One app was excluded due to its contact details 
and developer website being unidentifiable. Data for the 
missing 10 were determined by using information on each 
developer’s website relating to their web/smartphone 
app. Table 1 details, for each of the apps, the extent and 
nature of their indicators of quality, as derived from the 
responses of the developers to the survey or else from the 
interpretation of the apps’ websites, and table 2 shows a 
summary of key findings relating to the questions asked.
Clinical involvement
Overall 32 (68%) developers had clinical involvement 
in the development of their app. According to a Fisher’s 
exact test, there was a statistically significant association 
between app type and clinical involvement, p=0.037. 
The result suggests that web apps may have more clinical 
involvement than phone apps.
Academic involvement
Overall 18 (38%) developers had academic involvement 
in the development of their app. There was a statistically 
significant association between app type and academic 
involvement, χ2(1)=7.277, p=0.007. There was a moder-
ately strong negative association between app type and 
academic involvement, φ=−0.393, p=0.007. The result 
suggests that web apps may have more academic involve-
ment than phone apps.
Publications published or forthcoming
Overall 21 (45%) developers had publications published 
or forthcoming regarding their app. There was a statisti-
cally significant association between app type and whether 
there were any scientific articles published or forth-
coming, χ2(1)=16.492, p<0.000. There was a strong nega-
tive association between app type and articles published 
or forthcoming, φ=−0.592, p<0.000. The result suggests 
that web apps may have more papers published or forth-
coming than phone apps.
Other evidence
Overall 20 (43%) developers had other evidence 
regarding their app. There was a statistically signifi-
cant association between app type and other evidence, 
χ2(1)=8.684, p=0.003. There was a strong negative asso-
ciation between app type and other evidence, φ=−0.430, 
p=0.003. The result suggests that web apps may have more 
other evidence than mobile apps.
Psychological approach or theory
Overall 28 (60%) developers used a psychological 
approach or theory in their app. There was a non-sig-
nificant association between app type and psychological 
approach or theory, χ2 (1)=0.696, p=0.404. The result 
suggests that no difference in the use of psychological 
approaches or theories between web and phone apps.
DISCUSSION
The present study documented self-reported data 
regarding development information surrounding each of 
the web and smartphone apps used and recommended by 
the NHS for stress, anxiety and depression as identified in 
our previous study.13 Our data source was a survey sent to 
developers requesting information about clinical involve-
ment, academic involvement, publications published or 
forthcoming, other evidence of effectiveness and whether 
the app was based on a psychological approach or theory. 
In the absence of a response, we turned to websites. The 
purpose of doing this was to attempt to gauge the quality 
of the existing apps as providers of therapy without 
performing user trials on every one. The approach 
adopted has enabled a deeper examination of the 
processes that are employed in each app’s development.
The data presented indicates a significant disparity 
between web and phone-based applications. Web appli-
cations are indicated as being significantly higher in all 
areas of quality except for psychological approach. This 
gap in quality measures may stem historically from how 
the two technologies have evolved. Web applications for 
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mental health such as Beating the Blues18 originated in 
academia in the 2000s before being brought to market. 
Mobile apps began to appear in 2008 when app stores 
began to open.19 However, the process of developing 
mobile apps for mental health took a drastically different 
route to market that had more in common with the early 
1980s personal microcomputer boom20 whereby anyone 
with access to a personal microcomputer and a program-
ming book could publish their own software. Poor regula-
tion of mental health app quality and privacy21 on the one 
hand, and dramatic growth of innovation in the digital 
space on the other,22 has meant mobile apps have taken 
a similar path with home coders being able to create and 
publish mental health apps with minimal questioning of 
their quality.
The varying quality between the two app types is 
supportive of the issues and solutions discussed in the 
introduction to this study. However, even with the slow 
introduction of regulation, there still seems to be a 
limited amount of action to regulate mental health apps 
coming from the app stores themselves. Responsibility 
is being placed on app developers to get regulated, for 
users to check apps are regulated and for governments 
and health organisations such as the NHS to flag up apps 
that are regulated. A number of studies have examined 
the potential dangers and safety issues associated with 
apps aimed at the public and whether these apps should 
be assessed or controlled by various regulatory agencies, 
such as the MHRA in England.23
A systematic review by Donker et al,24 published 6 years 
ago supports the efficacy of mental health apps across all 
ages, but revealed a lack of published evidence for many 
e-therapy smartphone apps that were available. The results 
of the current survey have revealed a very similar trend 
to Donker’s findings, with only 27% of smartphone apps 
surveyed having any evidence of effectiveness published 
or forthcoming.
The survey results indicate web apps fared much better 
with 92% of app designers saying that their app had 
evidence of effectiveness. However, overall 44.7% of apps 
had published or forthcoming evidence of effectiveness. 
The lack of a consistent evidence base makes the process 
of finding an effective NHS e-therapy haphazard. During 
2018 the NHS rolled out a digital apps library designed 
to showcase a selected number of apps that have been 
through assessment and are safe to use.25 The ‘Mental 
Health’ section of the library contains 18 apps, four those 
apps appear in this study and account for 22.22% of the 
section: Big White Wall; Ieso; SilverCloud and Stress and 
Anxiety Companion.
It is vital that the NHS ensure this library contains 
apps that are supported by evidence, so service users are 
presented with effective apps. For a considerable amount 
of time NICE guidance for mental health practitioners was 
that computerised cognitive behaviour therapy (cCBT) 
could be offered for persistent subthreshold, or mild to 
moderate depression.26 However, this guidance was with-
drawn in July 2018 to allow OCFighter to be considered 
for an IAPT assessment briefing.26 Even with this with-
drawal a strong emphasis is still placed on the use of CBT 
within mental health services. The results of the survey 
indicated that at that time 60% of apps used a known 
psychological approach or theory. On further analysis, 
71% of the 60% used CBT, meaning 14% of those that 
declared using a psychological approach/theory were 
using an approach that was not NICE-approved, and 40% 
had no theory behind them at all.
Importantly, we have seen from this study that different 
criteria can be applied to evaluating apps. Regarding 
research evidence, developers have different interpre-
tations of this. Some felt that findings from third-party 
studies of the conventional, face-to-face delivery of the 
therapeutic model used within the app would translate 
into an indication of the app’s effectiveness, while others 
considered internal studies, evaluations and testing of 
elements such as the user interface to be a sufficient indi-
cation of app effectiveness.
This study is not without limitation, and there are areas 
which were not assessed, due to the need for brevity. 
However, future research would be well-advised to 
consider them. For example, questions querying service 
user and computer scientist involvement could have 
further expanded on the indicators of quality used within 
this study and opened further avenues of investigation. 
Assessment criteria that were released after this study 
was carried out such as NHS Digital’s assessment ques-
tionnaire V.2.111 investigate service user involvement by 
asking questions around the use of user centred design. 
Approximately 120 apps have been evaluated using the 
questionnaire.27 There are other potentially important 
areas that were unexplored in this study, such as the 
frequency of updates of the apps.28 Finally, the nature 
of data collection (brief self-report and website review) 
may have inherent limitations on the depth and quality of 
the information available. Definitions were not provided 
to respondents regarding what did and did not qualify 
as ‘academic involvement’, for example, and there may 
have been variation in the way that this was interpreted. 
One developer felt that the involvement of a PhD student 
met this criteria, but a research student versus senior a 
member of faculty have very different levels of expertise. 
Future research could seek to rectify this, by defining 
explicit categories of involvement and levels of expertise. 
Future research could also examine not only whether 
clinicians, academics, computer scientists and service 
users were involved in the development process, but also 
at what stage. It would be reasonable to hypothesise that 
early involvement here may result in a better product, as 
there would be more iterative design cycles into which 
relevant expertise could feed.
CONCLUSIONS
As an increasing number of developers are looking to 
produce e-therapies for the NHS it is essential they apply 
clinical and academic best practices to ensure the creation 
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of safe and effective apps. The present study has provided 
a snapshot of the commercial e-therapy development 
landscape and the areas that need the most refinement to 
improve their suitability for NHS mental health services. 
These are as follows:
1. The building of better working relationships with cli-
nicians to ensure e-therapy content is both beneficial 
and credible.
2. Creation of commercial app development projects with 
academics to enable increased innovation and to feed 
lessons learnt back to the research knowledge base.
3. Generation of published evidence through studies in 
areas such as piloting, feasibility, acceptability, effec-
tiveness and efficacy to help enable easy distinction of 
the effectiveness of an e-therapy.
4. Collection, analysis and publication of other evidence 
to back up claims of effectiveness.
5. Ensuring that a psychological approach or theory that 
is known to be empirically sound is applied within an 
app to help build credibility.
It should be noted that while the alternative methods 
of evaluation discussed in this study are relevant and 
timely, RCTs remain the pinnacle of quality evidence of 
effectiveness. The best way to synthesise such evidence 
is through meta-analysis. As such, future work should 
extend the current investigation beyond this initial devel-
oper survey, to synthesise the published evidence available 
for all e-therapies used and recommended by the NHS 
in England, thus establishing NHS delivered e-therapy 
effectiveness.
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